Differential diagnosis NETs may be highly challenging. In order to exclude conditions that may mimic a neuroendocrine neoplasms, a deep knowledge of all the aspects of the disease, together with an adequate capacity to interpret clinical data and imaging findings and to put them in right correlation, are strongly warranted. Patients which suspected neuroendocrine neoplasms should be referred to reference centers to receive optimal multidisciplinary care. Free full text available at www.tumorionline.it
Get full access to this article
View all access options for this article.
References
1.
YaoJ.C., HassanM., PhanA., DagohoyC., LearyC., MaresJ.E., AbdallaE.K., FlemingJ.B., VautheyJ.N., RashidA., EvansD.B.: One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. JCO 26;18: 3063–3072, 2008.
2.
RindiG., CapellaC., SolciaE.: Introduction to a revised clinicopathological classification of neuroendocrine tumors of the gastroenteropancreatic tract. Q J Nucl Med, 44(1): 13–21, 2000.
3.
FinkG., KrelbaumT., YellinA., BendavanD., SauteM., GlazerM., KramerM.R.: Pulmonary carcinoid: presentation, diagnosis and outcome: in 142 patient in Israel and review of 650 cases in literature. Chest, 119: 1647–1651, 2001.
4.
BajettaE., CatenaL., DucceschiM., PuscedduS., MilioneM., MaccauroM., BajettaR., ProcopioG., BuzzoniR., FormisanoB., Di GuardoL., PlataniaM.: Pitfalls in the diagnosis of neuroendocrine tumors: atypical clinical and radiological findings as cause of medical mistakes. Tumori, 95(4): 501–507, 2009.
SeregniE., FerrariE., BajettaE., MartinettiA., BombardieriE.: Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol, 12(suppl): S69–S72, 2001.
7.
BajettaE., FerrariL., MartinettiA., CelioL., ProcopioG., ArtaleS., ZilemboN., Di BartolomeoM., SeregniE., BomabardieriE.: Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer, 86(5): 858–865, 1999.
8.
GibrilF., ReynoldsJc, ChenC.C., YuF., GoebelS.U., SerranoJ., DoppmanJ.L., JensenR.T.: Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false positive in patient with gastrinomas. J Nucl Med, 21: 47–502, 1999.
9.
ReubiJ.C., LaissUeJ., WasserB., HorisbergerU., SchaerJ.C.: Expression of somatostatin receptors in normal, inflamed and neoplastic human gastrointestinal tissues. Ann NY Acad Sci, 733: 122–137, 1994.
Toth-FejelS., PommierR.F.: Relantionship among delay of diagnosis, extent of disease, and survival in patients with abdominal carcinoid tumors. Am J Surg, 187: 575–579, 2004.
